



EXPRESS MAIL NO. EV336654351US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ronald Berenson et al.
Application No. : 09/960,264
Filed : September 20, 2001
For : SIMULTANEOUS STIMULATION AND CONCENTRATION OF
CELLS

Examiner : L. Blaine Lankford
Art Unit : 1651
Docket No. : 980034.417C1
Date : April 21, 2004

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Fourth Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Supplemental Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

JAU:ljt

Enclosures:

Forms PTO-1449 (3 Sheets)
Cited References (36)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

\476129

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

980034.417C1

APPLICATION NO.

09/960,264

**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Ronald Berenson et al.

FILING DATE

September 20, 2001

GROUP ART UNIT

1651

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	6,544,788	04/08/03	Singh	435	383	
	BB	2001/0031253	10/18/01	Gruenberg	424	93.1	
	BC	2002/0090362	07/11/02	Strauss	424	93.21	
	BD	2002/0182730	12/05/02	Gruenberg	435	375	
	BE	2003/0039650	02/27/03	Gruenberg	424	144.1	
	BF	2003/0134341	07/17/03	Gruenberg	435	7.21	
	BG	2003/0134415	07/17/03	Gruenberg	435	372	
	BH	2003/0170238	09/11/03	Gruenberg	424	144.1	
	BI	2003/0175242	09/18/03	Gruenberg	424	93.2	
	BJ	2003/0175272	09/18/03	Gruenberg	424	144.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BK	WO 03/025158	03/27/03	WIPO		
	BL	WO 03/034820	05/01/03	WIPO		
	BM	WO 03/043643	05/30/03	WIPO		
	BN	WO 03/077658	09/25/03	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BO	Lanzavecchia, A., "The Role of Dendritic Cells in the Generation of Effector and Memory T Cell Responses," from <i>The Midwinter Conference of Immunologists</i> , January 22-25, 2000, available at www.midwconferimmunol.org/Midwinter00/sessions/lanzavecchia.html .
	BP	Li, Q. et al., "Expanded Tumor-reactive CD4 ⁺ T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation," <i>Clinical Cancer Research</i> 5: 461-469, February 1999.
	BQ	Li, Q. et al., "Immunological Effects of BCG as an Adjuvant in Autologous Tumor Vaccines," <i>Clinical Immunology</i> 94(1): 64-72, January 2000.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

980034.417C1

APPLICATION NO.

09/960,264

**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Ronald Berenson et al.

FILING DATE

September 20, 2001

GROUP ART UNIT

1651

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	5,443,983	08/22/95	Ochoa et al.	435	240.2	
AB	5,470,730	11/28/95	Greenberg et al.	435	172.3	
AC	5,674,704	10/07/97	Goodwin et al.	435	69.1	
AD	5,804,442	09/08/98	Romet-Lemonne et al.	435	374	
AE	6,113,901	09/05/00	Bluestone	424	154.1	
AF	6,143,297	11/07/00	Bluestone	424	184.1	
AG	6,129,916	10/10/00	Chang	424	179.1	
AH	6,197,298	03/06/01	Chang	424	179.1	
AI	6,316,257	11/13/01	Flyer et al.	435	372.3	
AJ	6,355,779	03/12/02	Goodwin et al.	530	388.23	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
AK	EP 633930 B1	04/26/00	EPO		
AL	WO 97/05233	02/13/97	WIPO		
AM	WO 97/05239	02/13/97	WIPO		
AN	WO 03/024312	03/27/03	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AO	Baroja, M.L. et al., "The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) Provides a Helper Signal and Bypasses the Need for Accessory Cells in T Cell Activation with Immobilized Anti-CD3 and Mitogens," <i>Cellular Immunology</i> 120: 205-217, 1989.
AP	Bergstresser, P.R. et al., "T Cell-Mediated Terminal Maturation of Dendritic Cells," in <i>Dendritic Cell in Fundamental and Clinical Immunology</i> , Ricciardi-Castagnoli (Ed.), Plenum Press, New York, 1997, pgs. 65-69.
AQ	Groh, V. et al., "Stimulation of T Cell Autoreactivity by Anomalous Expression of NKG2D and its MIC Ligands in Rheumatoid Arthritis," <i>Proceedings of the National Academy of Sciences</i> 100(16): 9452-9457, August 5, 2003.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
980034.417C1APPLICATION NO.
09/960,264**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS


Ronald Berenson et al.

FILING DATE

September 20, 2001

GROUP ART UNIT

1651

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA	2003/0194395	10/16/03	Gruenberg et al.	424	93.7	
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CK					
	CL					
	CM					
	CN					
	CO					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CP	Zou, J.-P. et al., "Tumor-Bearing Mice Exhibit A Progressive Increase in Tumor Antigen-Presenting Cell Function and A Reciprocal Decrease in Tumor Antigen-Responsive CD4 ⁺ T Cell Activity," <i>The Journal of Immunology</i> 148(2): 648-655, January 15, 1992.
	CQ	
	CR	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).